洞察市场格局
解锁药品研发情报

400客服电话

  • 购买数据产品

    400-9696-311 转1

  • 定制咨询业务

    400-9696-311 转2

  • 数据与AI定制业务

    400-9696-311 转3

  • 商务合作及其他问题

    400-9696-311 转4

  • 投诉及建议

    400-9696-311 转5

医药数据查询

【ChiCTR1800016588】Mindfulness based intervention for Chinese children with autism and their parents: a randomised controlled trial

基本信息
登记号

ChiCTR1800016588

试验状态

正在进行

药物名称

/

药物类型

/

规范名称

/

首次公示信息日的期

2018-06-11

临床申请受理号

/

靶点

/

适应症

孤獨症譜系障礙

试验通俗题目

Mindfulness based intervention for Chinese children with autism and their parents: a randomised controlled trial

试验专业题目

Mindfulness based intervention for Chinese children with autism and their parents: a randomised controlled trial

申办单位信息
申请人联系人
请登录查看
申请人名称
请登录查看
联系人邮箱
请登录查看
联系人邮编

联系人通讯地址
请登录查看
临床试验信息
试验目的

The objective of this randomized controlled trial is to examine the effectiveness of a mindfulness-based intervention specifically developed for children with ASD aged 8 to 18 years on their well-being, autism-related symptoms, behaviours, resilience, family relationship, mindfulness level and health service utilization, as well as their parents parental stress, well being, rumination, and health service utilization in Hong Kong, comparing to waiting list control.

试验分类
请登录查看
试验类型

随机平行对照

试验分期

治疗新技术

随机化

The randomisation will be conducted by an experienced independent statistician using computer-generated random results.

盲法

Participants will be informed of their group assignments. The research staff member who conducts the assessments or the statistical analysis will be kept blinded of the group assignment.

试验项目经费来源

The D. H. Chen Foundation, Hong Kong SAR

试验范围

/

目标入组人数

140

实际入组人数

/

第一例入组时间

2018-06-28

试验终止时间

2021-06-27

是否属于一致性

/

入选标准

Participants will include both children with ASD and their parents. The inclusion criteria will be (1) children aged 8-18 years who have been previously diagnosed with ASD by a doctor according to the Diagnostic and Statistical Manual of Mental Disorders-4/5 (DSM-4/5) diagnostic criteria; (2) and at least one of their parents agrees to participate.;

排除标准

The exclusion criteria will be: (1) being unable to communicate and understand Chinese language as the intervention will be conducted in Chinese; (2) having a medical condition rendering him/her to be incapable to participate in the study; (3) unwilling or unable to give consent.;

研究者信息
研究负责人姓名
请登录查看
试验机构

The D. H. Chen Foundation, Hong Kong SAR

研究负责人电话
请登录查看
研究负责人邮箱
请登录查看
研究负责人邮编

/

联系人通讯地址
请登录查看
更多信息
获取更多临床信息查看权限
立即前往摩熵医药企业版免费查询
示例数据
<END>

最新临床资讯

摩熵医药企业版
50亿+条医药数据随时查
7天免费试用

全球药物研发中心
全球研发数据与行业前沿情报

384,225
全球在研药物数
1,205
本月临床试验数
全球批准的新药
更多
全球首批
各国首批
数据来源:摩熵医药
更新时间:
研发动态
相关报告
政策法规
更多信息,请进入全球药物研发中心查看

医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测

2,630亿元
2026年Q2总销售额
6.14%(2026Q2)
TOP5企业市场份额
药品销售排行榜
查看完整数据
2025Q4医院化学药销售增速 *按市场份额排序
  • 1
    甲氨蝶呤注射液
  • 2
    克霉唑阴道乳膏
  • 3
    氯化钠注射液
核心能力
  • 医药市场销售数据分析 · 医院、实体药店、网上药店
  • 市场竞争格局分析(靶点、药品类型、ATC大类)
更多信息,请进入医药市场洞察中心查看